Amiodarone for sustained ventricular tachycardia: Efficacy, safety, and factors influencing long-term outcome

Bauman, Jerry L.; Berk, Steven I.; Hariman, Robert J.; Langenberg, Patricia; Deal, Barbara J.; Beckman, Karen J.; Brownstein, Sheldon L.; Gallastegui, Jose

doi:10.1016/0002-8703(87)90549-7

Cited by 25 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particular attention was paid to the clinical practice guidelines published by the North American Society of Pacing and Electrophysiology 26 . Although some amiodarone toxicities are dose‐related, 24 , 25 most monitoring recommendations in the literature are not dose‐specific. As such, our monitoring quality indicators did not vary with amiodarone dose.…”

Section: Methodsmentioning

confidence: 99%

“…The reported incidence of amiodarone‐induced toxicities varies, with some observational studies suggesting that between 34% and 93% of patients have some type of ADE during the course of therapy 23 . The development of toxicity appears to be dependent on the dose and duration of therapy 24 , 25 . Most side effects are mild, but serious toxicities warranting discontinuation of therapy have been reported in up to a quarter of patients 21 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice

Stelfox

Ahmed

Fiskio

et al. 2004

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

Current standards for amiodarone toxicity monitoring are based on expert opinion with limited evidence to support most recommendations. Monitoring practices appear to vary significantly, with few patients receiving all of the recommended monitoring. Some amiodarone-related adverse drug events may be preventable and patient safety might be improved with a better understanding of monitoring processes.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice

Stelfox

Ahmed

Fiskio

et al. 2004

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…The use of amiodarone is complicated by its very unusual pharmacokinetics and unwanted side‐effects. These aspects are both well covered by recent reviews [120, 121], and will only be briefly outlined here. The administration of amiodarone (normally by mouth) is complicated by variable bioavailability (20–80%), and a terminal half‐life of elimination which is usually 35–40 days, but may exceed 100 days.…”

Section: Class III Antiarrhythmic Agentsmentioning

confidence: 99%

Therapeutic drug monitoring: antiarrhythmic drugs

Campbell

Williams

1998

Brit J Clinical Pharma

View full text Add to dashboard Cite

Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast‐inward sodium channel on myocardium. These agents have a very significant toxicity, and while they are being used less, therapeutic drug monitoring (TDM) does significantly increase the safety with which they can be administered. Class II agents are antisympathetic drugs, particularly the β‐adrenoceptor blockers. These are generally safe agents which do not normally require TDM. Class III antiarrhythmic agents include sotalol and amiodarone. TDM can be useful in the case of amiodarone to monitor compliance and toxicity but is generally of little value for sotalol. Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. These are normally monitored by haemodynamic effects, rather than using TDM. Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline. TDM is very useful for monitoring the administration (and particularly the safety) of both of these agents.

show abstract

“…Administration of amiodarone, although often lifesaving, is associated with pulmonary side effects [1,2]. Patients with AIPT can present with either a chronic disorder that suggests pulmonary fibrosis or a more acute process.…”

Section: Discussionmentioning

confidence: 99%

“…Amiodarone-induced pulmonary toxicity (AIPT) is one of the most serious adverse effects of amiodarone therapy and can be fatal [1][2][3][4][5][6]. Onset of AIPT may be rapid, occurring within days, or, more commonly, insidious, occurring after several months of therapy.…”

Section: Introductionmentioning

confidence: 99%

Value of technetium-99m diethyltriamine pentaaceticacid radioaerosol inhalation lung scintigraphy for the stage of amiodarone-induced pulmonary toxicity

Durmuş-Altun¹,

Altun²,

Salihoğlu³

et al. 2004

International Journal of Cardiology

View full text Add to dashboard Cite

Amiodarone for sustained ventricular tachycardia: Efficacy, safety, and factors influencing long-term outcome

Cited by 25 publications

References 23 publications

Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice

Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice

Therapeutic drug monitoring: antiarrhythmic drugs

Value of technetium-99m diethyltriamine pentaaceticacid radioaerosol inhalation lung scintigraphy for the stage of amiodarone-induced pulmonary toxicity

Contact Info

Product

Resources

About